Telegram账号盗号云控破解技术|【唯一TG:@heimifeng8】|飞机盗号软件API破解技术✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨JAMA Neurology: Migraine drug fremanezumab reduces symptoms of depression, study suggests
An international team of researchers from the United States, Israel, Portugal, and some other countries has discovered a dual effect of the migraine drug fremanezumab. It turned out that the drug not only reduces the frequency of headaches, but also relieves depression.
The findings were published in the scientific journal JAMA Neurology.
It is known that migraine and depression are linked, as depression is 2-4 times more common in migraine sufferers. Both conditions can be caused by an imbalance in serotonin and glutamine.
Fremanezumab belongs to a class of monoclonal antibodies that block the CGRP protein, which is involved in the development of migraines.
The 28-week trial involved 540 patients from 12 countries—including the US and the EU countries. Those who received subcutaneous injections (225 milligrams) of fremanezumab showed a reduction in the number of migraine episodes per month and a reduction in depressive symptoms by the eighth week, compared with a placebo.
The researchers propose two mechanisms: a direct effect on general neurochemical processes, and an improvement in the psychological state of patients due to the absence of pain.
The findings open up new possibilities for treating complex cases of migraine combined with depression. However, the researchers emphasize the need for more research to determine the exact mechanisms of action of the drug.